AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Alzheimer’s Research UK is the UK’s leading dementia research charity specialising in finding preventions, causes, treatments and a cure for dementia. We believe that science and innovation hold the key to defeating dementia. We conduct world-class research to prevent, treat and cure dementia. We help people to understand dementia and the progress we are making. We forge partnerships with Government and other key organisations to make dementia research a national priority.
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. In October 2013 Astex became a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. The Otsuka Group employs approximately 43,000 people globally, and its products are available in more than 80 countries worldwide.
For more information about Astex Pharmaceuticals, please visit http://www.astx.com
For more information about Otsuka Pharmaceutical, please visit http://www.otsuka.com/en/
Eisai is one of the world’s leading research-based pharmaceutical companies. We define our corporate mission as “giving first thought to patients and their families, and to increasing the benefits health care provides,” which we call human health care (hhc). With operations in the U.S., Asia, Europe and it’s domestic home market of Japan, Eisai employs more than 11,000 people worldwide.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. The new name reflects the charity’s purpose: to be the arc or bridge between research and improving patients’ lives. LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research. So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance.
www.lifearc.org Twitter @lifearc1.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world’s most urgent medical needs.
Today’s MSD is a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.msd-uk.com.
If you are a pharmaceutical, biotechnology or academic organisation or a dementia charity and are interested in joining the consortium, please contact us.
Charities and companies that are interested in setting up similar consortiums for other disease areas should contact Mike Johnson at LifeArc.